alexa
Reach Us +44-1202068036
ENESTgoal: Evaluation Of Treatment-Free Remission (TFR) In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) And Sustained Deep Molecular Response (MR) Following Switch To Nilotinib | 19901
ISSN: 2155-9864

Journal of Blood Disorders & Transfusion
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

2nd International Conference on Hematology & Blood Disorders

Andrea Magley, Eric J Feldman, Michae W Deininger, Jerald Radich, Christopher Keir, Felice Lin and Michael Mauro
Posters: J Blood Disorders Transf
DOI: 10.4172/2155-9864.S1.007
Abstract
Sustained TFR has been reported in clinical trials ofpatients withCML-CP who achievedsustaineddeep MR on imatinib therapy. Nilotinib treatmentresults in high rates of sustained deep MR, a key eligibility criterion for TFR studies.The randomized, phase 2 ENESTgoal study(NCT01744665) will evaluate TFR among patients with CML-CP who achievesustained MR4.5 (BCR-ABL≤0.0032% on the International Scale [IS] by real-timequantitative polymerase chain reaction [RQ- PCR]) after switching tonilotinib.ENESTgoal will enrollapproximately 300 patients with major molecular response (BCR- ABLIS≤0.1%)but with detectable disease (BCR-ABLIS>0.0032%), as assessed by a central laboratory, after ≥1 year ofimatinib therapy. Patients will switch to nilotinib 300 mg twice dailyonstudy entry andbe monitored quarterly for up to 2 years; those who achieveconfirmed MR4.5 during the monitoring phase will be randomized to enter a 1- or 2-year consolidation phaseof continuednilotinib treatment. Patients will then stop nilotinib therapy and enter the 3-year TFR phase if MR4.5is maintained throughout the consolidation phase. RQ-PCR assessments will be performed monthly for the first 6 months of the TFR phase, then every 2 months for 18 months and then quarterlythereafter. Patients with molecular relapse, defined in ENESTgoalas confirmed loss of MR4 (or BCR-ABLIS>0.01%), will re-initiate nilotinibtherapy. The primary endpoint of the study is the molecular relapse-free rate at 6 months after suspension of nilotinib therapy. ENESTgoal is currently open for enrollment in the United States.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri and Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version